Thr110
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr110  -  RBM7 (human)

Site Information
HVGNssPtstsPSRY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3245495

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , phosphopeptide mapping ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
PF3644022 ( 1 ) , SB203580 ( 1 ) , UV ( 1 )

References 

1

Blasius M, et al. (2014) A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response. Genes Dev 28, 1977-82
25189701   Curated Info

2

Mulhern D (2011) CST Curation Set: 12712; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

3

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info